Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib in severe indolent systemic mastocytosis
NCT04333108Phase 3Unknown
- Sponsor
- AB Science
- Start
- Jul 2020
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of masitinib in indolent systemic mastocytosis (ISM), smoldering systemic mastocytosis (SSM), sponsored by AB Science. Status: unknown.
02
Drugs
masitinib
03
Conditions
indolent systemic mastocytosis (ISM)smoldering systemic mastocytosis (SSM)
Beyond the preview
Go deeper on NCT04333108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04333108.